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G protein-coupled receptors (GPCRs) mediate our sense of vision,
smell, taste, and pain. They are also involved in cell recognition and
communication processes, and hence have emerged as a prominent
superfamily for drug targets. Unfortunately, the atomic-level struc-
ture is available for only one GPCR (bovine rhodopsin), making it
difficult to use structure-based methods to design drugs and muta-
tion experiments. We have recently developed first principles meth-
ods (MembStruk and HierDock) for predicting structure of GPCRs, and
for predicting the ligand binding sites and relative binding affinities.
Comparing to the one case with structural data, bovine rhodopsin, we
find good accuracy in both the structure of the protein and of the
bound ligand. We report here the application of MembStruk and
HierDock to 1-adrenergic receptor, endothelial differential gene 6,
mouse and rat I7 olfactory receptors, and human sweet receptor. We
find that the predicted structure of 1-adrenergic receptor leads to a
binding site for epinephrine that agrees well with the mutation
experiments. Similarly the predicted binding sites and affinities for
endothelial differential gene 6, mouse and rat I7 olfactory receptors,
and human sweet receptor are consistent with the available experi-
mental data. These predicted structures and binding sites allow the
design of mutation experiments to validate and improve the structure
and function prediction methods. As these structures are validated
they can be used as targets for the design of new receptor-selective
antagonists or agonists for GPCRs.
GPCR  olfactory receptor  -adrenergic receptor  endothelial
differentiation gene  taste receptor
G protein-coupled receptors (GPCRs) mediate senses such asodor, taste, vision, and pain (1) in mammals. In addition,
important cell recognition and communication processes often
involve GPCRs. Indeed, many diseases involve malfunction of these
receptors (2), making them important targets for drug develop-
ment. Unfortunately, despite their importance there is insufficient
structural information on GPCRs for structure-based drug design.
This is because these membrane-bound proteins are difficult to
crystallize, and the atomic-level structure has been solved only for
bovine rhodopsin (3, 4). Consequently, it is important to develop
theoretical methods to predict the structure and function of
GPCRs (5, 6).
Experimental data relevant to the function of GPCRs is available
for ligand activation of GPCRs (7–15) and site-directed mutagen-
esis (16–18). This data has led to information about structural
features in the ligand-binding regions of GPCRs (refs. 5 and 19, and
references therein). Protein sequence analyses on GPCRs reveals a
common protein topology consisting of a membrane-spanning
seven-helix bundle, which likely accommodates the binding site for
low-molecular-weight ligands. Structurally, GPCRs can be classi-
fied as (i) GPCRs with short N terminus (5–80 residues) and
(ii) GPCRs with a long N-terminal ectodomain (80–600 resi-
dues). The long N terminus of class II GPCRs may be involved in
the ligand recognition (8), but ultimately the bound ligand probably
moves into the transmembrane (TM) region to activate the G
protein.
To provide structural and ligand-binding information on GPCRs,
we have been developing computational strategies and techniques
for predicting:
Y the tertiary (three-dimensional) structure of GPCRs by using
only the amino acid sequence (MembStruk), and
Y binding site and binding energy of various ligands to GPCRs
(HierDock).
The first report on these developments (20, 21) focused on olfactory
receptors (ORs) because ligand-binding data were available for 24
simple organic molecules to 14 different ORs (14). In this article we
report the structure and function prediction of GPCRs for four
classes for which there is no three-dimensional structure:
Y 1-adrenergic receptor (1AR),
Y endothelial differentiation gene (EDG6),
Y rat and mouse I7 ORs, and
Y human sweet receptor.
In addition we validate our techniques by predicting the three-
dimensional structure of bacteriorhodopsin and bovine rhodopsin
for which crystal structure data are available. The function predic-
tion technique is validated for retinal bound to bovine rhodopsin.
The predicted ligand binding sites and the ordering of binding
energies for the other GPCRs calculated here are consistent with
the experimental data on ligand activation measurements and also
site-directed mutation studies. Thus, the predicted binding site of
cis-retinal when using just the protein crystal structure of bovine
rhodopsin leads to a rms deviation in coordinates (CRMS) error of
0.6 Å from the crystal structure of the retinalrhodopsin complex.
The system with the most complete site-directed mutagenesis
experiments to characterize the active site is epinephrine-
adrenergic receptor (AR). We find that our predicted binding site
is in excellent agreement with the conclusions from experiment.
Thus, the predicted structures should be useful in
Y designing mutagenesis experiments to validate the structure of
the binding site,
Y predicting the natural ligands binding to specific GPCRs,
Y designing specific drugs for GPCRs, and
Y predicting mutations to make the GPCRs specific for new
ligands.
The next section summarizes various details of the MembStruk and
HierDock methods. In addition, we validate these methods by
comparing to experimental data for rhodopsin and bacteriorho-
dopsin. This is followed by results and discussion for the five GPCRs
and by conclusions in the last section.
Abbreviations: AR, -adrenergic receptor; 1AR, 1-adrenergic receptor; CRMS, rms
deviation in coordinates; EDG, endothelial differentiation gene; GPCR, G protein-coupled
receptor; OR, olfactory receptor; TM, transmembrane.
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Computational Methods
Force Fields. For the protein, we have used the DREIDING FF
(22) with charges from CHARMM22 (23) or charge equili-
bration (QEq) method (24). For the ligands we used the
DREIDING FF with Gasteiger charges (25). For the lipids we
used the DREIDING FF with QEq charges. The calculations
treated the solvent (water) by using the continuum solvation
methods such as Surface Generalized Born (SGB) (26) or the
Analytical Volume Generalized Born (AVGB) (27) methods.
The MembStruk Protocol for Predicting Structures of GPCRs. The
MembStruk protocol for predicting structures of TM proteins
consists of the following steps:
1. Prediction of TM regions.
2. Construction and optimization of individual helices.
3. Assembly of the seven-helical TM bundle.
4. Coarse grain optimization of the TM bundle.
5. Addition of interhelical loops and optimization of the full
structure.
Step 1. We developed the TM2NDS program that determines TM
regions in GPCRs using hydropathicity analysis (28, 29) calculated
using the Eisenberg hydrophobicity scale (29), combined with input
from multisequence profiles. The multisequence alignment profile
is obtained from the sequence analysis for a particular family of
GPCRs. For example, the sequence analysis for ORs used 23 rat
and mouse ORs reported by Singer et al. (30). TM2NDS analyzes the
hydrophobicity profile of all of the sequences used in the alignment
and assigns the TM regions by using capping rules for helices.
Step 2. The canonical right-handed-helices were then built with
extended side chains and optimized using the NEIMO torsional
molecular dynamics (MD) method (31–33), with fixed bonds and
angles. This allows for sequence-specific distortions in the helix,
such as for proline, and also the optimization of the side chain
conformations.
Step 3. Each helical axis was oriented according to the 7.5-Å
electron density map of bovine rhodopsin (34). The hydrophobic
moments of the NEIMO-optimized helical bundle were aligned so
that the net hydrophobic moment of each helix would be pointing
outward toward the membrane from the center of mass.
Step 4. We have developed a dynamics program, COARSEROT,
that performs coarse-grain rotation of the helical orientations,
starting with the directions of the net hydrophobic moment of each
helix from Step 3. Each helix is rotated through a grid of rotation
angles about its helical axis. The total energy of this helix in the field
of all of the other helices (fixed) is minimized using conjugate
gradients. After finding the optimum configuration for each specific
helix, we then go through a second cycle (seven such optimizations)
and continue until the energy converges. We then add two layers of
explicit lipid molecules (52 molecules of dilauroylphosphatidyl
choline lipid) that were optimized with the current configuration of
the seven helices. Then, to achieve proper packing of the TM
helices, the seven-helix-bilayer complex is further optimized with
rigid-body MD of the seven helices and lipid for 100 ps.
Step 5. Following the rigid-body dynamics, loops were added to
the helices by using WHATIF software (35). We then identified the
possible disulfide linkages among the conserved cysteines across all
GPCRs (36, 37) and added disulfide bonds where there are close in
the predicted structure. It is plausible to consider the disulfide
linkages among conserved cysteines in the TM region earlier in the
protocol, but the disulfide linkages among the loops are added at
this step to constrain the loop conformation. After the addition of
loops and disulfide linkages, we used SCWRL (38) to add the side
chains for all of the residues and then performed a full-atom MD
optimization of the structure by using MPSim (39), with the explicit
lipids.
Structure Validation. Structure prediction for bacteriorhodopsin.
MembStruk was first tested on bacteriorhodopsin, which is not a
GPCR but a seven-helical transmembrane protein for which crystal
structures have been solved at various activated states and mutants
with resolutions varying from 3.5 Å (40) to 1.55 Å (41).
We started from the sequence of bacteriorhodopsin and
predicted the structure by using MembStruk without any infor-
mation from the crystal structure studies. We used diphosphati-
dyl glycerophosphate (the lipid present in the purple membrane
from Halobacterium halobium) bilayers to describe the mem-
brane. The CRMS of C atoms in the predicted structure for the
residues in the TM region is 3.3 Å and 2.9 Å compared with the
crystal structures (2BRD and 1C3W) with resolutions of 3.5 Å
and 1.55 Å, respectively. Including the loops, the overall CRMS
for all 221 amino acids is 8.6 Å and 6.2 Å. Of course, the loop
regions are much less well defined in the crystal structure studies
and may be affected by packing forces in the crystal.
Structure prediction for bovine rhodopsin. The only GPCR
for which the crystal structure is available is bovine rhodopsin (3, 4),
with a resolution of 2.8 Å. To predict this structure with
MembStruk, we carried out a multiple sequence alignment using
CLUSTALW (42), considering the sequence of rhodopsin plus eighty-
five other sequences, having sequence identity between 99% and
40%, picked from a BLAST search (ref. 43; this computation was
performed at the Swiss Institute of Bioinformatics by using the
BLAST network service). The assigned TM regions differ by an
average of two residues from the crystal structure. This alignment
implied a disulfide linkage between residues Cys-110 and Cys-187.
We then used MembStruk to predict structure for rhodopsin. This
differs by CRMS 3.1 Å from the C atoms of the crystal (Fig. 1A).
The individual helices differ from the crystal structures by CRMS
of 1.0 Å for helix 1, 2.1 Å for helix 2, 1.2 Å for helix 3, 1.1 Å for helix
4, 1.8 Å for helix 5, 2.2 Å for helix 6, and 1.6 Å for helix 7. The crystal
structure is missing 10 residues in loop regions, and 13 residues
are missing their side-chain atoms. Of course, the calculated
structure has all atoms of all residues. Thus, to compare with
experiment we ignore the missing residues and atoms. The remain-
ing residues (including loops) of the predicted structure differ from
the crystal structure by 8.3 Å CRMS. The major contribution to this
CRMS is the low-resolution loop region. We will next consider
binding of the ligand to this predicted structure to determine
whether 3 Å accuracy in the TM region is adequate for predicting
the ligand binding site.
Function Prediction for GPCRs. With the exception of rhodopsin, our
only test on the validity of the predicted GPCR structures will be
to compare with experimental ligand activation data. Thus, it is
essential that we have a reliable and efficient procedure for
predicting binding-site and relative-binding affinities of ligands in
GPCRs. Because the ligand binding site is not known in many
GPCRs, the entire protein should be scanned to identify likely
binding sites and then the relative binding energies of the ligands
calculated in these sites. For this purpose we use the HierDock
protocol (20, 44), which has been applied successfully to both
globular and membrane proteins (20, 45, 46).
HierDock Protocol. The HierDock ligand screening protocol (44)
follows a hierarchical strategy for examining ligand binding con-
formations and calculating their binding energies. This involves the
use of coarse-grain docking methods to quickly scan the entire
GPCR to locate the most plausible proteinligand complexes,
followed by molecular mechanicsdynamics (MMMD) simula-
tions (including continuum solvation) of these good structures by
using more accurate scoring functions. The steps in HierDock are
as follows.
Coarse-grain docking—level 1. First we carried out a coarse-grain
docking procedure [currently using DOCK 4.0 (47)] in which a
number of ligand conformations are sampled in the void regions
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within the receptor. The void regions described using spheres
generated over the whole receptor (using the SPHGEN program in
DOCK4.0). No assumptions were made on the nature or the location
of the binding site in these receptors. We then generated and scored
(using the DOCK scoring function) 1,000 configurations for each
box, keeping the 10% (100) of the best scoring structures.
Fine-grain optimization—level 2. We then minimized the energy
of the ligand (with protein fixed) for the 100 structures from level
1 by using the Dreiding FF and QEq charges. These 100 minimized
structures are ranked by using both energy and solvation.
All-atom optimization—level 3. Ten percent of the best struc-
tures from level 1 are further minimized with all atoms both protein
and ligand movable. Each structure was scored using the binding
energies: BE  Energy (free ligand)  Energy (free protein) 
Energy (ligand–protein complex), where the system is solvated for
each case by using AVGB solvation method.
Scanning the Entire Receptor for Binding Sites. We used the molec-
ular surface of the protein to define potential binding regions within
the receptor. We then partitioned the void region in the entire
receptor into 10–15 overlapping docking boxes, each with a volume
of (10 Å)3. We excluded regions in contact with the membrane or
near the intracellular region likely to be involved in binding to the
G protein. Steps 1 and 2 of the HierDock protocol were applied first
to a ligand known to activate the GPCR, scanning the entire GPCR
structure to locate the most favorable ligand binding site(s). We
then defined the ‘‘binding region’’ as the protein site where most of
the best scoring ligands clustered. If there is more than one site with
clusters of good ligand binding energies, we treated them equally as
potential binding regions. Then we defined the binding region as a
cube having 10 Å on each side centered at this site(s).
Docking of the Library of Ligands in the Binding Region. We then
docked the entire library of potential ligands for the receptor to this
binding region and calculated their relative binding energies (steps
2 and 3 of HierDock). The ligands were then ranked by binding
energy. This procedure assumes that the same binding site is used
for all ligands that bind to the receptor. An ambiguity here is that
we cannot be sure that binding to this site will lead to G-protein
release, which is usually the basis of the experimental measure-
ments (rather than binding affinity).
Validation for Function Prediction Protocol for cis-RetinalBovine
Rhodopsin. To validate the HierDock protocol for GPCRs, we
predicted the binding of cis-retinal to the crystal minimized struc-
ture of bovine rhodopsin. First we extracted the bovine rhodopsin
structure plus bound rhodopsin from the 2.8-Å-resolution crystal
structure and added all of the missing residues in the loops and also
the missing side-chain atoms by using PolyGraf. Hydrogens and
counterions Na and Cl were added energy of the protein–ligand
complex was minimized. We refer to this structure as ‘‘crystal
minimized.’’ Then cis-retinal was removed from this ‘‘crystal min-
imized’’ rhodopsin protein structure for docking. The cis-retinal
used for docking was built and minimized with the DREIDING FF
and Gasteiger charges with the AVGB continuum solvation
method for the free ligand. Although this ligand is covalently bound
to Lys-296 in the crystal structure of rhodopsin, for docking we used
the full cis-retinal ligand (replacing the CON bond in the crystal
with CHO and adding an H to Lys-296). The rhodopsin from the
‘‘crystal minimized’’ structure was partitioned into 13 overlapping
regions for step 1 of HierDock. The final optimized best binding
structure for the retinalrhodopsin complex from step 3 of Hier-
Dock is compared with the crystal structure in Fig. 1B. The docked
cis-retinalrhodopsin leads to a CRMS difference of 1.2 Å with the
crystal structure. The docked structure has a distance of 2.8 Å
between the C atom of OCHO group of retinal C and the
side-chain N of Lys-296 (‘‘CN bond,’’ to which it should bond
covalently after eliminating H2O to form the Schiff base). We then
made this covalent CN bond to Lys-296 and reminimized the
ligand–protein structure. This leads to CRMS difference of 0.62 Å
between the cis-retinal of the docked and crystals structures. We
consider that these results validate the HierDock protocol. This test
is a blind prediction of the binding site of cis-retinal without using
any experimental information on the binding site of cis-retinal in
bovine rhodopsin.
For the GPCRs considered in this paper, we do not have an
experimental protein structure, and it is important to know how
well HierDock can predict ligand binding by using the predicted
structure from MembStruk. Thus, we applied HierDock (steps 1–3)
to determine the binding site of cis-retinal in the predicted structure
of rhodopsin. Without covalent attachment of the ligand to Lys-296,
the final optimized structure of cis-retinal is 2.8 Å CRMS from the
crystal structure with the CN bond being 8.1 Å. A second criteria
for validity in the predicted binding site is identifying the residues
close to the ligand. We find that residues G114, A117, T118, G121,
E122, L125, H211, Y268, A292, and A295 are within 5 Å of both
the ligand binding sites. Thus, we conclude that the MembStruk
predicted structure can be used for predicting binding sites suffi-
ciently well to direct mutation studies.
Results and Discussion
In this section we present the structure and function prediction
using MembStruk and HierDock for 1AR, EDG6, mammalian I7
ORs, and human sweet receptor.
Fig. 1. (A) Comparison of predicted structure for bovine rhodopsin (green)
with the x-ray crystal structure (blue). The TM regions have a CRMS of 3.1 Å.
(B) Comparison of the HierDock predicted structure of cis-retinalRhodopsin
to the crystal structure.
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1 Adrenergic Receptor. The AR family plays an extremely im-
portant role in mediating the sympathetic nervous response. All
members of the AR subfamily respond to similar native catechol-
amine ligands (epinephrine and norepinephrine). Genes exist in
most animals for nine different subclasses of three 1 receptors
(1A, 1B, 1D), three 2 receptors (2A, 2B, 2C), and three 
receptors (1, 2, 3) expressed in different tissues and leading to
different responses. 1AR is expressed primarily in cardiac tissue,
where it regulates blood pressure and heart rate in responses to
stress. A major problem in designing drugs for the AR family is
the cross interaction of drugs among these subtypes. For example,
-blockers meant to act on only 1AR, also activate other subtypes
of AR. Hence, to design subtype receptor-specific drugs it is
essential to have the structure of each of the subtypes of AR.
Deletion mutagenesis and proteolytic cleavage studies of the
AR show that most of the connecting hydrophilic regions can be
deleted without affecting ligand binding properties, suggesting that
the ligand binding site is in the barrel of the TM region (48).
Mutation of Asp-138 reduces the binding to both agonists and
antagonists (16, 17), suggesting that this residue is involved in
binding and that agonists and antagonists might have similar
binding sites. Mutation experiments show clearly that the two ortho
catecholOOH groups make hydrogen bond contacts with Ser-229
and Ser-232 (5). The amine group of epinephrine makes a hydrogen
bond with Asp-138 (16). Our structure also predicts that Asp-138
forms a hydrogen bond with the OH group of the alkyl chain in
epinephrine.
We used MembStruk to predict the structure of 1AR. For the
TM region predictions, the sequences from 1 to 4 subtypes were
aligned. The third intracellular loop of 1AR is 74 residues long.
Scanning the entire 1AR receptor led to three possible binding
regions. We then minimized the structure of the receptor with
epinephrine for each of these three sites and carried out a second
HierDock calculation by using the optimized sites. One of the three
regions (shown in Fig. 2A) emerged clearly as the best binding site
for epinephrine. We find that TMs 3, 5, and 6 are involved in the
binding of epinephrine (as suggested experimentally). Fig. 2B
shows the residues involved in the binding of epinephrine. Indeed,
we find hydrogen bond contacts of epinephrine with residues
Asp-138, Ser-229, and Ser-232. In addition, we find a hydrophobic
interaction with Phe-341 (seen above the catechol ring). These four
residues were all identified experimentally as necessary for ligand
binding to the AR (12, 13, 15). We find that Ser-229 and Ser-232
form hydrogen bonds with meta and para OH groups of the
catechol ring, respectively, just as found experimentally.
In summary, the binding conformation predicted with HierDock
matches precisely the results from all experimental studies. This
validates both the MembStruk and HierDock protocols, suggesting
that accuracy of 3 Å for structure prediction in the TM regions
is adequate to identify binding site and structure.
EDG6 Receptor. The EDG receptor subfamily of GPCRs is impli-
cated in diverse biological processes such as cell proliferation,
differentiation, and migration, making it important for clinical
applications. Based on sequence homology the EDG receptor
family is partitioned into two major subgroups. The s1p subgroup
(comprised of EDG1, EDG3, EDG5, EDG6, and EDG8) responds
to sphingosine-1-phosphate (s1p), whereas the lysophosphatidic
acid (lpa) subgroup (comprised of EDG2, EDG4, and EDG7)
responds to lpa. For EDG6 we consider the ligands s1p as a positive
and lpa as a negative (12) ligand.
Using MembStruk, we predicted the structure of EDG6 receptor
and then applied HierDock scanning on EDG6 with s1p to deter-
mine its binding site. This leads to the structure in Fig. 3, where the
s1p binding site lies between TM3 and TM7. Fig. 3 shows that
residues W291, E284, and T127 are important in recognizing the
s1p ligand and shows other residues within 3 Å of the ligand. We
Fig. 2. (A) Predicted binding site of epinephrine in the predicted structure of
1-adrenergic receptor. (B) Residues within 5 Å of epinephrine bound to 1-
adrenergic receptor. Shown in bold are the three residues Asp-138, Ser-229, and
Ser-232 (deduced from mutation experiments to be involved in binding).
Fig. 3. Residues within 5 Å of the sphingosine-1-phosphate in the predicted
structure of EDG6.
Vaidehi et al. PNAS  October 1, 2002  vol. 99  no. 20  12625
A
PP
LI
ED
BI
O
LO
G
IC
A
L
SC
IE
N
CE
S
propose that mutation of residues W291, E284, and T127 will affect
the binding of s1p to EDG6. The calculated binding energy for s1p
is 7.6 kcalmol more favorable than for lpa, which is consistent with
the experimental data on the radiolabeled binding assay measure-
ments for s1p and lpa to the EDG6 receptor (12).
Mammalian ORs. ORs form one of the largest gene families in the
genome, with 1,000 different proteins believed to interact with a
range of odorant molecules. Unlike AR and EDG receptors, each
OR is broadly tuned to recognize many odorants. Each odorant
elicits a response from a combination of ORs (14) so that olfactory
perception depends on a complex set of ligand-recognition
interactions.
Predicted Binding Site of Aldehydes for Mouse I7 and Rat I7 OR. The
mouse and rat I7 ORs differ by only 15 residues, four of which are
in the TM domains. But their odorant binding profile is thought to
be different. Thus, Krautwurst et al. reported (11) that rat I7
recognizes n-octanal and n-heptanal, whereas mouse I7 recognizes
only n-heptanal. On the other hand, Bozza et al. recently reported
(7) that both mouse and rat I7 are activated by both n-octanal and
n-heptanal. Using MembStruk, we predicted independent struc-
tures for both rat and mouse I7. The CRMS difference between all
atoms in the TM region is 1.7 Å. This is consistent with the 95.4%
homology between the two sequences. The calculated binding
energies show a difference in binding energy of 0.2 kcalmol
between octanal and heptanal in rat I7 and a difference of 0.3
kcalmol in mouse I7. Hence, we find that there is little or no
preference for n-octanal over n-heptanal for these receptors, as
predicted by the model of Singer (30) and in agreement with the
experiments of Bozza et al. Of course, these minor differences might
lead in a difference in the activation of G protein second-messenger
pathway (the process observed experimentally).
Fig. 4 shows the predicted binding site for n-octanal in rat I7 (very
similar to that for heptanal). TM helices 3, 4, and 6 form the binding
cavity. As indicated by the dotted line in Fig. 4, Lys-164 forms a
hydrogen bond and is critical in recognizing the aldehyde functional
group for both octanal and heptanal, in agreement with previous
modeling of rat I7 by Singer et al. (30). Mutation of this residue
should switch receptor specificity toward other functional groups.
Other residues important in binding are Phe-109, Cys-114, Cys-117,
and Ile-255, which we suggest for mutational studies. We find that
none of the sequence differences between rat I7 and mouse I7 are
located near the binding pocket, supporting the similarity of binding
profiles found by Bozza et al. (7).
Human Sweet Receptor. The sweet and bitter receptors have been
identified (9, 13, 49, 50) to be GPCRs, with fewer sweet receptors
than bitter receptors. J. Liao and P. G. Schultz (private communi-
cation) recently identified the sequence for human sweet receptor.
This sequence has an extracellular N terminus of 600 residues.
Using MembStruk, we predicted the structure of this receptor
without the N terminus. Using HierDock, we calculated the binding
energies for a library of 65 tastants (J. Liao and P. G. Schultz,
private communication), including a variety of sugars, amino acids,
artificial sweeteners, bitter tastants, and other tastants. Fig. 5 shows
the predicted binding site of trehalose. It involves residues in TM
domains 1, 2, 3, and 7 plus Lys-785 [located in extracellular loop
Fig. 4. Binding site of octanal in rat I7 OR.
Fig. 5. Binding site of trehalose in human sweet receptor. This shows
residues within 3 Å of trehalose and includes the hydrogen bonds to Ser-798,
Ser-646, and Lys-785.
Fig. 6. Comparison of the predicted binding sites for GPCRs: white, bovine
rhodopsin; green, rat I7 OR; blue, mouse I7 OR; red, 1AR.
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(EC) 3]. We found all 12 sugars to be anchored to Ser-646 and
Ser-798 through hydrogen bonds, suggesting them for mutation
studies. the top 15 tastants selected using the dual criteria of strong
binding and contacts to Ser-646 and Ser-798 are sweet molecules,
supporting our predictions. A table for these results can be viewed
at www.wag.caltech.eduGPCR. It is possible that the N terminus
(not considered here) also plays a role in recognition sugars to be
exposed to the TM regions.
Comparison of Binding-Site Location in Various GPCRs. Fig. 6 shows
the location of the important residues involved in ligand binding for
four of the five GPCRs studied here. We find that TM 2, 3, 4, 5, and
7 are involved in the recognition of ligand. The spheres in white
show important residues for binding of cis-retinal in bovine rho-
dopsin, whereas those in red shows the residues found in the binding
region for -adrenergic receptors. The other spheres show residues
involved in binding to the other GPCRs. We find that the residues
involved in binding are in similar spatial location for most of the
GPCRs and agree well with known experimental results. The
strictly conserved D(E)RY sequence in all these GPCRs is present
in the intracellular loop 2 (IC2) connecting TM3 and TM4.
The function of GPCRs is to couple ligand binding in the
extracellular region to G-protein activation in the intracellular
region. Based on these results we propose the following model for
the initiation of signaling. After the ligand is bound to the GPCR,
the extracellular loop 2 may close down over the barrel, perhaps by
recognizing the exposed side of the ligand or of a part of the TM
region that responds to the binding of ligand. The crystal structure
of bovine rhodopsin shows just such a closed loop. The dramatic
movement of EC2 in response to ligand binding may cause helix 3
to translate in the cytoplasmic direction, exposing the D(E)RY
sequence to the cytoplasmic region near the G protein. This might
initiate the signal transduction pathway. We hope to use our
predicted structures in dynamical studies to test such ideas.
Summary
We predict the structure and function for four classes of GPCRs,
1AR, EDG6, human sweet receptor, and mouserat I7 olfactory
receptors, for which there are no known experimental structures.
We validated our predicted protein structures by comparing
to the crystal structure for bovine rhodopsin, with an accuracy of
3.0 Å for the TM regions. HierDock prediction of the binding site
of cis-retinal in bovine rhodopsin gives an accuracy of 0.6 Å for the
crystal rhodopsin structure and 2.8 Å for the predicted rhodopsin
structure.
The binding site for epinephrine in 1AR is in excellent agree-
ment with mutation experiments. The structure and function
prediction for all GPCRs are in good agreement with the experi-
mental ligand activation data currently available. These structures
suggest additional site-directed mutagenesis studies to test the
predicted structure and function of GPCR.
Our GPCR structures can also be used to predict new ligands that
would bind to specific GPCRs, providing additional tests of our
predicted structures. Such experiments will be useful to further
refine the predicted structure and function. Our predicted GPCR
structures should also be useful for predicting the function of
orphan GPCRs.
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